**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 77634

**Manuscript Type:** MINIREVIEWS

**Heterogeneity of immune control in chronic hepatitis B virus infection: Clinical implications on immunity with interferon-α treatment and retreatment**

Yin GQ *et al*. IFN-α retreatment and immunity

Guo-Qing Yin, Ke-Ping Chen, Xiao-Chun Gu

**Guo-Qing Yin, Ke-Ping Chen, Xiao-Chun Gu,** Center of Hepatology, Zhong-Da Hospital, Southeast University, Nanjing 210009, Jiangsu Province, China

**Author contributions:** All authors contributed to the study conception and design; The first draft of the manuscript was written by Yin GQ; All authors commented on previous versions of the manuscript, they all read and approved the final manuscript.

**Corresponding author: Guo-Qing Yin, MD, PhD, Chief Doctor, Chief Physician,** Center of Hepatology, Zhong-Da Hospital, Southeast University, No. 87 Dingjiaqiao, Nanjing 210009, Jiangsu Province, China. yingq62@sina.com

**Received:** May 10, 2022

**Revised:** September 8, 2022

**Accepted:** October 9, 2022

**Published online:**

**Abstract**

Hepatitis B virus (HBV) infection is a global public health issue. Interferon-α (IFN-α) treatment has been used to treat hepatitis B for over 20 years, but fewer than 5% of Asians receiving IFN-α treatment achieve functional cure. Thus, IFN-α retreatment has been introduced to enhance antiviral function. In recent years, immune-related studies have found that the complex interactions between immune cells and cytokines could modulate immune response networks, including both innate and adaptive immunity, triggering immune responses that control HBV replication. However, heterogeneity of the immune system to control HBV infection, particularly HBV-specific CD8+ T cell heterogeneity, has consequential effects on T cell-based immunotherapy for treating HBV infection. Altogether, the host’s genetic variants, negative-feedback regulators and HBV components affecting the immune system's ability to control HBV. In this study, we reviewed the literature on potential immune mechanisms affecting the immune control of HBV and the clinical effects of IFN-α treatment and retreatment.

**Key Words:** Hepatitis B virus;Chronic; Functional cure; Heterogeneity; Immunity; Immune control; Interferon-α; Retreatment

Yin GQ, Chen KP, Gu XC. Heterogeneity of immune control in chronic hepatitis B virus infection: Clinical implications on immunity with interferon-α treatment and retreatment. *World J Gastroenterol* 2022; In press

**Core Tip:** Hepatitis B virus (HBV)-specific immune control is characterized by distinct phenotypical and functional profiles. Owing to the negative feedback associated with all immune responses in an infected host, immunomodulators regulating a single immune pathway are unlikely to fully restore antiviral immunity. Interferon-α (IFN-α) treatment was shown to simultaneously affect multiple immune pathways and various immune cell populations in the host and integrate signals toward improving HBV-specific immune control. In addition, IFN-α retreatment was shown to improved functional cure rates, indicating that could gradually enhance the overall immune control.

**INTRODUCTION**

Hepatitis B virus (HBV) infection is a major global health problem. It is estimated that over 257 million people are suffering from chronic hepatitis B (CHB) infection[1]. After being infected by HBV, the virus transfers its genome into the nucleus of hepatocytes, where it is converted into covalently closed circular DNA (cccDNA), which has two major roles: Acting as a template for virus replication and acting as a reservoir for long-term virus preservation. Some studies have found that cccDNA persists in the hepatocytes of patients even decades after HBV infection has been resolved[2]. Further, it was shown that part of the viral genome remained integrated into the genomic DNA of the host’s hepatocytes. Therefore, targeted eradication of cccDNA and viral genome in hepatocytes is regarded as the holy grail for curing HBV[3-5], which has not yet been achieved with current therapies.

HBV infection induces various immune responses that lead to heterogeneous immune control associated with the HBV infection[5,6]. Acute HBV infection can be terminated by the host’s adaptive immune responses, characterized by multi-specific and vigorous HBV-specific CD8+ T cell responses. In contrast, during CHB infection, the adaptive immune responses are severely depressed due to exhausted or reduced HBV-specific CD8+ T-cells[6,7] and dysfunctions in HBV-specific B cells[7-9]. Researchers have noticed different outcomes from HBV infection in different populations and races.

Most CHB cases in the Asian population occur during infancy or childhood. However, asymptomatic infection during childhood makes it very challenging for authorities to determine when the infection actually occurred. Further, due to the uncertain timing of hepatitis flares and disease phases, there is little research on this topic in past literature, and little is known about hepatitis flares and intrahepatic immunity. Recently, studies on the partial immune mechanism in CHB have been performed, and important discoveries were made[2-6].

Currently, CHB is treated with nucleoside/nucleotide analogs (NAs) or interferon-α (IFN-α). NAs can target HBV polymerase/reverse transcriptase, inhibit HBV replication and are better tolerated by patients, but they cannot target cccDNA and unavoidably often results in NAs resistance and associated mutations. Since NAs do not directly influence immune response, functional cure with NAs is rarely achieved. In contrast, IFN-α treatment enhances HBV-specific immune control and can result in a partial or functional cure. However, due to poor efficacy with single course IFN-α treatment, since 1996, researchers have begun using IFN-α retreatment to improve the antiviral efficacy in CHB patients[10-15] or sufferers from NAs multi-drugs resistance[15-18].

In this present article, we reviewed the complex interactions between immune cells and cytokines of the immune response network against HBV, the correlation between host genetic variations and hepatitis B, the interplay between HBV components and HBV-specific immune control, and the heterogeneity of HBV-specifical immune control. Based on this foundation, we also discussed the underlying mechanism of IFN-α treatment and retreatment for improved HBV-specific immune control.

**HETEROGENEOUS IMMUNITIES DURING HBV INFECTION**

The innate and adaptive immunity work together to control immune responses against HBV. Innate immunity is not HBV antigen-specific but still produces T-cell polarizing and inflammatory cytokines that alter the intrahepatic microenvironment for presenting HBV antigens to naïve T cells to establish HBV-specific immunity. In recent years, researchers have recognized adaptive immunity as a crucial player for persistent and efficient immune control of HBV infection, which comprises a complex web of effector cell types. HBV-specific T cells help clearing HBV-infected hepatocytes and reduce the levels of circulating virus, while B cells neutralize viral particles and prevent reinfection[3,19-22]. Thus, their levels ultimately determine the outcome of the disease.

The liver is an immunologically tolerant organ in which most immune cells are suppressed to limit hypersensitivity of immune responses against organ damage and local antigens. Thus, in a healthy state, the proportion of immune cells within the liver is much lower than in the peripheral blood. The difference in immune statuses between the liver and peripheral blood is defined as “immune compartmentalization”. Investigations into the effects of costimulation have shown that Toll-like receptors (TLRs) and Treg cells participate in the intrahepatic immunopathogenesis in patients with HBV infection[3,23-25].

***Recognition of HBV components by the innate immunity***

Non-specific recognition of HBV components occurs at the molecular/subcellular level by innate immunosensors, namely pathogen-recognition receptors (PRRs) that recognize pathogen-associated molecular patterns (PAMP). The main PRRs that sense viral infection consists of retinoic acid-inducible gene I (RIG-I)-like receptors, nucleotide-binding oligomerization domain-containing protein-like receptors, TLRs, DNA-sensing receptors and C-type Lectin. These PRRs are expressed in epithelial cells, endothelial cells and immune cells. When PRRs interact with their cognate PAMP, downstream signaling pathways cascade, including adaptor/co-adaptor molecules, kinases and transcription factors are activated. This leads to the expression of interferon-stimulated genes (ISGs) and NFκB-inducible or pro-inflammatory genes, and various inflammatory cytokines are secreted. Primary cytokines include various classes of IFNs, pro-inflammatory cytokines and chemokines. These cytokines recruit various immune cells to the HBV-infected site, causing direct or indirect antiviral actions. These immune responses induce T cell proliferation and increase the efficiency of HBV-specific CD8+ T cells[21,26,27]. In particular, TLRs in hepatocytes and hepatic non-parenchymal cells (NPCs) have been shown to play vital roles in antiviral immunity. Currently, the use of TLR agonists as therapeutic agents to treat CHB is being validated[7].

In addition to cytokines, innate effector cells also participate in the control of HBV infection. Innate effector cells, including natural killer (NK) cells, γδT cells and mucosal-associated invariant T cells, can restrain the virus but are not specific for controlling HBV. Activated NK cells can induce inflammation in the liver, while activated T cells can be killed by NK cells, thereby reducing HBV-specific T cells. Although NK cells can suppress HBV replication, their activity was shown to be inhibited by transforming growth factor β (TGF-β) and IL-10 in CHB patients[3]. In addition, hepatic PCs, such as KCs and liver sinusoidal endothelial cells, can stimulate innate and adaptive immunity against HBV infection[28,29].

In short, the activation of innate immunity can lead to the production of cytokines, enhance antigen presentation, alter the intrahepatic microenvironment and trigger adaptive immunity (Figure 1).

***HBV infection and adaptive immunity***

HBV-specific T cells play a vital role in controlling HBV infection, and their immune responses can lead to the resolution of HBV replication. In acute hepatitis B patients, spontaneous viral clearance can occur *via* multi-specific CD8+ T cell responses against HBV components[3,30]. In contrast, in CHB, the patients suffer from the exhaustion of HBV-specific CD8+ T-cell responses throughout the HBV infection. Thus, most research on immune dysfunction focus on the activity of T cells, including CD8+ and CD4+ T-cells.

CHB is associated with the exhaustion of HBV-specific CD8+ T-cells, marked by compromising functionality, such as reduced production of antiviral cytokines and immunodulatory cytokines and impaired proliferative capacities, defined as T-cell exhaustion[31,32]. HBV-specific CD8+ T-cell exhaustion can be induced by: (1) Gradual aggravation of CD8+ T-cells dysfunction and decreasing inflammatory cytokines production; (2) Increase in checkpoint inhibitors and immunosuppressive cytokines; (3) Epigenetic alterations leading to unrecoverable CD8+ T-cell functions; (4) Alterations in CD8+ T-cell phenotype; (5) Mitochondrial dysfunction and glycolysis downregulation, (6) Decrease in cell detection rate; and (7) Terminal exhaustion and physical deletion of HBV-specific CD8+ T-cells.

In acute hepatitis B, CD4+ T-cells have an important but indirect role in cleaning the virus. Th1-polarized CD4+ T-cells regulate and maintain CD8+ T-cell responses, contributing to HBV clearance. In contrast, during chronic HBV infection, the activation and upregulation of CD4+CD25+ Treg-cells suppress effective antiviral immune responses by inhibiting IFN-γ secretion, which inhibits the proliferation and cytokine secretion of CD4+ and CD8+ T-cells[7,30]. Figure 1 illustrates the complex interactions between immune cells and cytokine within the immune response network. The immune cells and their related cytokines are presented in Table 1.

***HBV components inhibit innate and acquired immunity***

HBV is believed to have existed in the human population for thousands of years and evolved with humans. During this evolution process, HBV has developed a particular lifecycle based on its unique replication mode through cccDNA and viral components that can adapt and suppress its host's immunity. Although the innate immunity can differentiate between different HBV components, HBV virion, antigens and peptides are still able to attack the TLR signaling pathway, resulting in negligible ISGs or IFNs secretions[4,7].

Among the ISGs is the apolipoprotein B editing complex (APOBEC) gene. APOBEC3A/B has been shown to cause cccDNA degradation, while APOBEC3G can inhibit HBV replication. However, APOBEC3G expression is often reduced by HBsAg[32].

A viral protein known for influencing HBV replication is HBx. It can interact with the cellular proteins in hepatocytes to increase viral replication by impairing IFN signaling and enhancing HBV gene expression[33-35]. Further, it was shown that HBV antigens could inhibit CD8+ T-cell efficiency. Antagonist functions may provide a means for HBV to escape immune detection. Considering that certain CD8+ T-cell epitopes in hepatitis B core antigen (HBcAg) or HBsAg can act as T-cell receptor (TCR) antagonists, their binding to TCR can lead to the suppression of CD8+ T-cell response, thus decreasing their efficiency (Figure 2). In addition, the chronicity of HBV infection was shown to be promoted by HBeAg *via* the induction of CD8+ T-cell tolerance[36].

***Mechanisms of immune escape in antigen-presenting cells/HBV specific-CD8+ T-cells***

When the HBV protein is swallowed by antigen-presenting cells (APCs), this protein is digested into tiny pieces, which are transferred onto human leukocyte antigen (HLA) antigens. The HLA antigen complex on APCs is then displayed to T cells, which produce effector molecules to eliminate HBV. However, when HBV enters a hepatocyte, it enhances intracellular survival at the expense of higher levels of HBV replication. Thus, HBV-infected hepatocytes produce a large number of HBV antigens that can, in turn, inhibit HBV antigen processing and presentation in APCs. Further, amino acids flanking the viral epitopes in APCs play a critical role in antigen processing. Mutations at these regions in HBV infection harm the proteasomal processing of epitopes and lead to CD8+ T-cell escape[30].

HLA genes are critical for the immune system as they control pathogens and clear infections. Host HLA polymorphisms have been demonstrated to influence disease progression in HBV infection[37]. Studies found that changes in the surface expression of HLA class I complexes on APCs were associated with HBV replication and persistence. Lower HLA class I expression led to early HBeAg seroconversion, while down-regulation of HLA class II molecules led to pre-core mutants of HBcAg[38]. Lumley *et al*[30] focused on the interplay between the immune escape of HBV and the selective mutation of HLA-binding residues. They reported that this selective mutation of HLA-binding residues in CD8+ epitopes could induce the immune escape of HBV, which is one of the most commonly identified mechanisms for HBV-specific CD8+ immune escape[30].

N-linked glycosylation (NLG) is a post-translational modification that can impact the infectivity and antigenicity of HBV. It can mask immune epitopes, leading to immune escape and interfering with the antibody recognition of hepatitis B surface antigen. NLG can also affect the ability through which the envelope protein of HBV interacts with the surface of capsids to drive HBV virion secretion[30].

The connection between TCR on T-cell and HLA class I/peptide complexes induces the activation of CD8+ T-cells, but alterations in TCR recognition, *i.e.*, epitope mutations in TCR contact residues, can lead to the immune escape of CD8+ T-cells. Immunodominance of HBV epitopes is ensured by the amino acid sequence of the peptide and its concentration and binding affinity with T cell clones. In different CD8+ T-cell clones, the same viral peptide can induce different signaling cascades[22]. Figure 2 illustrates the immune escape of HBV, which can occur through multiple pathways. This has a vital role in HBV infection that can last for decades, with some T cell defects being irreversible.

***Negative feedback regulation in immune response pathways***

Negative feedback regulations commonly occur in immune response pathways. These regulations include negative regulation of immune signal pathways (*i.e.*, negative feedback regulation in TLRs pathway), activation of immune checkpoints, expression of inhibitory cytokines, and activation of inhibitory immune cells. An active innate immunity can induce the secretion of cytokines with antiviral activity, enhance the efficiency of APCs and alter the microenvironment of the liver. However, inflammatory cytokines such as IFNs and tumor necrosis factor-α (TNF-α) can induce immune tolerance[39-41]. Many immune cells and signaling pathways in the liver contribute to immune responses against HBV infection. These immune responses are contact-dependent and can be affected by environmental factors. Inhibitory molecules are produced by hepatic stellate cells, Kupffer cells, T-regulatory cells and myeloid-derived suppressor cells. Through a contact-dependent manner, NK cells can kill HBV-specific CD8+ T-cells. Moreover, HBV-specific CD8+ T-cells can be suppressed by inhibitory ligands such as programmed death-ligand 1 (Figure 1)[6,42]. However, considering HBV has adaptive and active strategies to evade innate immune responses and negative feedback exists in all immune responses, immune regulator therapy targeting only a single pathway is unlikely to be effective in treating HBV infection.

***Host genetic variations associated with HBV infection***

Researchers have made great efforts to confirm the associations between HBV infection and host immunogenetics. Host genetic variants, including mutations in TLRs, HLAs, vitamin D-related genes, cytokine and chemokine genes, microRNAs, and HBV receptor sodium taurocholate co-transporting polypeptide, have been observed to impact the outcomes of HBV infection (Table 2)[43-46]. The HLA genes are divided into two classes: HLA-class I (HLA-A, B, C, E, F and G) and HLA-class II (HLA-DP, DQ, DR, DM and DO). Polymorphisms in HLA genes were shown to be significantly associated with the pathogenesis of HBV infection[47,48]. Studies have also reported that the genes encoding cytokines such as interleukins, TNF-α, IFNs and TGF-β, can influence the immune state of CHB patients[49-53]. In a study by Nitschke *et al*[54], the authors confirmed that specific HLA class I alleles restricted the efficacy of HBV-specific CD8+ T-cells[54], indicating that the host’s immune-related genes can affect the outcome of hepatitis B infection.

Researchers have observed significant differences in HBV infection rates between Western and East/Southeast Asian populations. Prior to HBV vaccination programs, the prevalence of HBsAg was less than 1% in the Caucasian population but higher than 10% in the Chinese population[43]. This difference was investigated in several studies, which showed that HLA molecules in European, Caucasian, Middle East, African-American and Asian populations affected the rate of HBV infection[43,55,56]. In addition, discordances in HBV-specific CD8+ T-cell repertoires observed in different races, i.e., between Chinese and Caucasian populations, could be related to race-dependent HLA gene variants, leading to the different T-cell responses observed between different populations and ethnicities[57].

Thus, these findings underline the complexity of HBV-specific immune control efficacy, which is influenced by HBV components, negative feedback regulation in immunity and host genetic variants (Figure 3).

***Heterogeneity of immune control in HBV infection***

Heim *et al*[6] reviewed the heterogeneity of HBV-specific CD8+ T-cells and described the functional deficiencies and distinct phenotypical characteristics associated with HBV-specific CD8+ T-cells exhaustion. T-cell impairment demonstrates hierarchical and progressive loss in antiviral functions, from functional suppression to physical deletion in T-cells, which depend on the quantity of HBV antigens and the duration of T cell exposure to these antigens[31,58]. Moreover, exhausted CD8+ T-cells do not represent a homogeneous T-cell population but are rather heterogeneous in function and phenotype. Kuipery *et al*[5] proposed concepts related to the heterogeneity of immune responses in CHB patients[5]. Based on reports from literature, we summarized the following concepts to improve our understanding on the heterogeneity of immune control.

Figure 1 illustrates the activation and inhibition of immune signaling pathways that overlap in HBV infection, multiple immune cell populations and integrated signals pathways that simultaneously respond to the stimulation of HBV components, and the ability of HBV-specific immune control depends on the overall immune responses of an individual rather than the capability of single immune cells or a single immune pathway.

Based on the immune escape mechanisms of APCs/CD8+ T-cells presented in Figure 2, the heterogeneous immune responses of T-cells are related to very fine mechanisms of immune regulation that influence the immune control of HBV-specific T-cells, or T-cells sensitivity/inhibition.

Figure 3 outlines the reasons for heterogeneous immune control. The overall immune control against HBV in an individual is influenced by HBV, negative feedback regulation in the immune signaling network and host genetic variants. Therefore, any changes in these three countenances could lead to fluctuations affecting the effectiveness of immune control. Thus, CHB infection is divided into four clinical phases: Immune tolerant with HBeAg-positive, HBeAg-positive immune-activation, inactive carrier with HBeAg-negative, and HBeAg-negative immune-activation. Further, heterogeneous immune controls can lead to different clinic phases and disease outcomes such as acute hepatitis, chronic hepatitis, cirrhosis, hepatocellular carcinoma and hepatic failure[43].

Reports have shown that host genetic polymorphisms are crucial determinants influencing HBV infectious rate and disease outcomes in Caucasian, Saudi Arabian, African-American, European, and Asian populations[56,59,60]. In addition, the host genetic variants of individuals from the same race can influence disease outcomes and the efficacies of antiviral therapy.

Researcher and immunologists who often overlook immune compartmentalization should be cautious when interpreting findings from the peripheral blood of patients.

**IFN-α TREATMENT FOR CHB**

***Definition of partial cure and functional cure***

A complete cure from HBV infection is currently hypothesized to be possible if the cccDNA and integrated HBV DNA are eliminated from hepatocytes. However, this is challenging as cccDNA can still persist in patients despite spontaneous recovery from an acute HBV infection. Since 2017, some advances in CHB therapeutics have been achieved[61], and researchers have proposed new definitions of cure. For instance, a partial cure has been defined as persistently undetectable HBV DNA and HBeAg in patients’ serum after the completion of a limited course of antiviral therapy. Functional cure has been defined as sustained and undetectable HBV DNA and HBsAg in patients’ serum, with or without seroconversion to hepatitis B surface antibody (anti-HBs), after a limited course of therapy. Complete sterilizing cure has been defined by the absence of HBsAg and eradication of HBV DNA, including HBV virion, integrated HBV DNA and cccDNA in the liver and serum of patients. However, because current treatments cannot deliver complete sterilizing cure, functional cure is the selected goal of therapy.

***NAs and immunotherapy***

Therapeutic strategies for CHB can be classified into two categories: NAs targeting HBV replication and immune modulators targeting immune control. NAs can cause rapid decay of HBV DNA in the peripheral blood but cannot completely eradicate HBsAg from patients' serum and cccDNA in hepatocytes[62,63]. Even though the virus might be undetectable in the serum after long-term treatment with NAs, low-level viral replication still persists due to the conservation of cccDNA in the nucleus of hepatocytes. Thus, prolonged NAs treatments are rarely associated with CHB cure and inevitably result in either NAs resistance or viral relapse[62-66].

In contrast, immunotherapy can target the innate and adaptive immunity to reinvigorate the host immune response to long-term inhibition of viral replication. Therapeutic strategies involving innate immunity include activating pattern recognition receptors (*i.e.*, TLRs and RIG-I), enhancing cytokine secretion, and improving the efficacy of NK cells. For adaptive immunity, therapies are directed at restoring the effects of HBV-specific T-cells and B-cells. Clinically, although immunotherapy can lead to sustained HBsAg loss, it cannot eradicate cccDNA from hepatocytes. Thus, being the more promising treatment compared to NAs, the ultimate goal of immunotherapy is currently targeted at achieving functional cure, enabling spontaneous control of HBV replication and maintaining disease remission without antiviral therapy[3]. Hoogeveen and Boonstra[32] reported that immunomodulators regulating a single immune pathway might not restore antiviral immunity as multiple immune pathways in the host enhance specific HBV immune responses[32].

***Mechanism and clinical application of IFN****-α* ***therapy***

IFNs are produced and released by immune cells in response to HBV components[67,68]. Of the known IFNs, IFN-α has broad-spectrum effects on viruses and tumors, and contributes to immune regulation by suppressing viral replication and cell growth. The antiviral function of IFN-α is cascaded by binding to IFN receptors on immune cells, activating signal transcription pathways, and inducing ISGs expression and related product secretion. Various ISGs products were found to inhibit different stages of the viral life cycle[69]. Further, epigenetics was shown to play a critical role in regulating cccDNA transcription[70-73]. IFN-α can regulate the epigenetic repression of cccDNA transcription by inducing cccDNA-bound histone hypo-acetylation and increasing the recruitment of transcription co-repressor on cccDNA[63,65,73]. In addition, IFN-α can upregulate HLAs expression to activate innate and adaptive immune responses. Many researchers have investigated the host genes associated with IFN-α treatment outcomes and observed its genetic polymorphisms[43,44,74-78] (Table 3).

As described earlier, due to negative feedback mechanisms, immune modulators targeting a single signal pathway might not improve the overall and long-term immune responses[61]. In this regard, the advantages of IFN-α treatment are that IFN-α can simultaneously affect multiple immune pathways and various immune cell populations in the host and integrate signals to improve the efficacy of immune control[10,11,15,36]. Currently, only IFN-α treatment was found to improve the efficacy of immune control[64,65].

IFN-α has been approved for the treatment of hepatitis B for over 20 years[36,61,65]. Compared with NAs, IFN-α has shown better efficacy in HBeAg seroconversion and HBsAg loss, with no risk of drug resistance[79]. For groups of patients with good prognoses, such as Caucasians, young age, low viral load, and females, IFN-α treatment has been more effective[80,81]. One study reported functional cure in 10%–20% of Caucasians who underwent IFN-α treatment, while it was < 5% in Asian patients[82]. However, most of the underlying mechanisms of IFN-α therapy are still unclear. More research is needed to investigate these significant differences in IFN-α efficacy between different groups of patients.

**IMPROVEMENT OF HBV-SPECIFIC IMMUNE CONTROL BY IFN-α RETREATMENT**

***IFN-α retreatment***

In 1996, although IFN-α was already being used to treat CHB patients, only 20%-30% of the patients achieved viral suppression or partial cure with single IFN-α treatment. Then, it was found that IFN-α retreatment in these remaining patients could enhance treatment outcomes. Thus, multiple courses of IFN-α were implemented to treat these patients and researchers observed that three courses of IFN-α treatment were effective in treating HBeAg positive or negative patients. With multiple frequencies of IFN-α treatment, partial or functional cure rates gradually increased to approximately 25%-40% but were mostly observed in patients of white race[10-14] (Table 4).

By 2008, failures from combination therapy with nucleoside and nucleotide were reported, and multi-drug resistance with NAs treatment started to increase in China. Comparatively, IFN-α retreatment was associated with safe stopping of NAs administration and induced better-sustained responses to IFN-α[15]. Thus, when researchers started to investigate the effects of increasing the frequency and extending the total course of IFN-α treatment and found that these could significantly improve the rate of functional cure in Asian and Caucasian patients[73-75,80-83]. IFN-α retreatment was recommended by the Asian-Pacific clinical practice guidelines[16-18] and by Yin *et al*[64] (Table 4).Based on these promising findings and recommendations, we estimate that more CHB patients in Asia would receive IFN-α retreatment and experience better antiviral efficacy.

***Interplay between IFN-α retreatment and the HBV-specific immune control***

Recently, more and more HBV-specific immune mechanisms have been discovered, inspiring clinicians and immunologists to collaborate to study the interplay between immune mechanisms and clinical events in hepatitis B. Chang *et al*[84] summarized the relationship between hepatitis flare and immune responses in CHB patients to explore the underlying immune mechanism of hepatitis flares[84]. The observations made from the strategy of Chang's *et al*[84] were used below to discuss the immune control involved in IFN-α retreatment.

Asymptomatic persistence of cccDNA in the liver of patients who had acute hepatitis B or self-limiting HBV infection, despite the resolution of HBV infection[3], indicates that the host’s immune system can fully inhibit HBV replication and that the specific HBV immune control in these individuals had an overwhelming advantage over HBV replication. In addition, investigations on the heterogeneous immune control of HBV infection have shown that the heterogeneity depends on the interplay between the host, virus and therapy, including host genes and immunity state, HBV load, duration of HBV infection, and IFN-α treatment and course of treatment[5,6,31,58]. However, the exact mechanism *via* which IFN-α retreatment exerts its benefits is yet to be fully elucidated.

Apart from HBV load, HBsAg and HBeAg, markers associated with the immune control of IFN-α treatment are lacking. In a study by Konerman and Lok[79], the authors proposed a scoring system that could help assess the efficacy of immune control[79]. The type of immune control could be estimated from a patient’s HBV DNA, HBeAg seroconversion, HBsAg loss and times of IFN-α treatment, based on the following criteria: (1) Patients with acute hepatitis B or self-limiting HBV infection could achieve automatic cure without IFN-α treatment; (2) Patients with acute hepatitis B could achieve functional cure with one time IFN-α treatment; (3) CHB patients with one time IFN-α treatment could achieve functional cure; (4) CHB patients with one time IFN-α treatment could achieve partial cure; (5) CHB patients with multiple times of IFN-α treatment could achieve functional cure; and (6) CHB patients with multiple times of IFN-α treatment could achieve partial cure. These criteria suggest a step-like decline in immune control with increasing infection severity.

Clinical studies have confirmed that IFN-α retreatment could gradually increase the rate of partial and functional cure (Table 4)[10,11,13,15,36] and that CHB patients often have diverse HBV-specific immune control. Since 2016, researchers in China have reported numerous findings from clinical trials in which patients with inactive HBsAg carriers or low-level viremia were selectively enrolled and treated with IFN-α to evaluate their functional cure rate[85-88]. However, it should be noted that these were performed under trial settings because clinical guidelines do not recommend IFN-α therapy for the treatment of CHB in these patients[16,89,90]. A high rate of functional cure, 44.7%-84.2% of HBsAg loss and 20.2%-68.2% of HBsAg seroconversion were reported, in which a distinctive pattern of immune control whereby a close correlation between lower HBsAg at baseline and higher rates of HBsAg loss or HBsAg seroconversion was observed[85-88]. This pattern also appeared in the final course of IFN-α retreatment in previous studies[10,11,13,15,36], indicating that reducing HBsAg could be a prerequisite for achieving functional cure during IFN-α retreatment.

Taken together, current literature indicates that IFN-α retreatment could gradually enhance the overall immune control and improve the antiviral efficacy of IFN-α in CHB patients (Figure 4).

**CONCLUSION**

The interactions between immune cells and cytokines form a complex immune response network that exerts immune control over HBV infection. The efficacy of HBV-specific immune control is affected by HBV components, negative feedback regulation in the immune system, host genetic variants, and heterogeneity in the function and phenotype of immune control to HBV. Treatment with IFN-α can simultaneously affect multiple immune pathways and various immune cell populations in the host and integrate signals to improve the efficacy of immune control. Clinically, increasing the frequency and extending the total course of IFN-α retreatment have improved functional cure rates, indicating that IFN-α retreatment could gradually enhance the overall immune control. Further research on IFN-α retreatment could help promote this strategy in CHB patients with.

Altogether, this article outlined immune control without detailed discussions on immunity-related markers during immune transformation. In future studies, the discovery of detailed markers associated with immune transformation could provide important clues in understanding the underlying mechanism of immune control to improve the treatment of HBV infection.

**ACKNOWLEDGEMENTS**

We are very grateful to Prof. Gao-Jun Teng in Zhong-Da Hospital, Southeast University and Prof. Bei Zhong in the sixth Affiliated Hospital of Guangzhou medical University/Qingyuan People’s Hospital for the comprehensive evaluation of the manuscript and valuable advices. Authors acknowledge Dr. Cun Shan in the Department of infectious disease, Nanjing Zhong-Da Hospital for data collection.

**REFERENCES**

1 **Revill PA**, Chisari FV, Block JM, Dandri M, Gehring AJ, Guo H, Hu J, Kramvis A, Lampertico P, Janssen HLA, Levrero M, Li W, Liang TJ, Lim SG, Lu F, Penicaud MC, Tavis JE, Thimme R; Members of the ICE-HBV Working Groups; ICE-HBV Stakeholders Group Chairs; ICE-HBV Senior Advisors, Zoulim F. A global scientific strategy to cure hepatitis B. *Lancet Gastroenterol Hepatol* 2019; **4**: 545-558 [PMID: 30981686 DOI: 10.1016/S2468-1253(19)30119-0]

2 **Rehermann B**, Thimme R. Insights From Antiviral Therapy Into Immune Responses to Hepatitis B and C Virus Infection. *Gastroenterology* 2019; **156**: 369-383 [PMID: 30267712 DOI: 10.1053/j.gastro.2018.08.061]

3 **Gehring AJ**, Protzer U. Targeting Innate and Adaptive Immune Responses to Cure Chronic HBV Infection. *Gastroenterology* 2019; **156**: 325-337 [PMID: 30367834 DOI: 10.1053/j.gastro.2018.10.032]

4 **Lang J**, Neumann-Haefelin C, Thimme R. Immunological cure of HBV infection. *Hepatol Int* 2019; **13**: 113-124 [PMID: 30600480 DOI: 10.1007/s12072-018-9912-8]

5 **Kuipery A**, Gehring AJ, Isogawa M. Mechanisms of HBV immune evasion. *Antiviral Res* 2020; **179**: 104816 [PMID: 32387476 DOI: 10.1016/j.antiviral.2020.104816]

6 **Heim K**, Neumann-Haefelin C, Thimme R, Hofmann M. Heterogeneity of HBV-Specific CD8+ T-Cell Failure: Implications for Immunotherapy. *Front Immunol* 2019; **10**: 2240 [PMID: 31620140 DOI: 10.3389/fimmu.2019.02240]

7 **Ma Z**, Cao Q, Xiong Y, Zhang E, Lu M. Interaction between Hepatitis B Virus and Toll-Like Receptors: Current Status and Potential Therapeutic Use for Chronic Hepatitis B. *Vaccines (Basel)* 2018; **6** [PMID: 29337856 DOI: 10.3390/vaccines6010006]

8 **Burton AR**, Pallett LJ, McCoy LE, Suveizdyte K, Amin OE, Swadling L, Alberts E, Davidson BR, Kennedy PT, Gill US, Mauri C, Blair PA, Pelletier N, Maini MK. Circulating and intrahepatic antiviral B cells are defective in hepatitis B. *J Clin Invest* 2018; **128**: 4588-4603 [PMID: 30091725 DOI: 10.1172/JCI121960]

9 **Salimzadeh L**, Le Bert N, Dutertre CA, Gill US, Newell EW, Frey C, Hung M, Novikov N, Fletcher S, Kennedy PT, Bertoletti A. PD-1 blockade partially recovers dysfunctional virus-specific B cells in chronic hepatitis B infection. *J Clin Invest* 2018; **128**: 4573-4587 [PMID: 30084841 DOI: 10.1172/JCI121957]

10 **van Zonneveld M**, Honkoop P, Hansen BE, Niesters HG, Darwish Murad S, de Man RA, Schalm SW, Janssen HL. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. *Hepatology* 2004; **39**: 804-810 [PMID: 14999700 DOI: 10.1002/hep.20128]

11 **Manesis EK**, Hadziyannis SJ. Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B. *Gastroenterology* 2001; **121**: 101-109 [PMID: 11438498 DOI: 10.1053/gast.2001.25524]

12 **Niederau C**, Heintges T, Lange S, Goldmann G, Niederau CM, Mohr L, Häussinger D. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. *N Engl J Med* 1996; **334**: 1422-1427 [PMID: 8618580 DOI: 10.1056/NEJM199605303342202]

13 **Carreño V**, Marcellin P, Hadziyannis S, Salmerón J, Diago M, Kitis GE, Vafiadis I, Schalm SW, Zahm F, Manzarbeitia F, Jiménez FJ, Quiroga JA. Retreatment of chronic hepatitis B e antigen-positive patients with recombinant interferon alfa-2a. The European Concerted Action on Viral Hepatitis (EUROHEP). *Hepatology* 1999; **30**: 277-282 [PMID: 10385667 DOI: 10.1002/hep.510300117]

14 **Ballauff A**, Schneider T, Gerner P, Habermehl P, Behrens R, Wirth S. Safety and efficacy of interferon retreatment in children with chronic hepatitis B. *Eur J Pediatr* 1998; **157**: 382-385 [PMID: 9625334 DOI: 10.1007/s004310050834]

15 **Yin GQ**, Zhong B. Efficacy of interferon for chronic hepatitis B in patients with nucleoside and nucleotide combination therapy failure. *J Gastroenterol Hepatol* 2016; **31**: 248-255 [PMID: 26456953 DOI: 10.1111/jgh.13191]

16 **Sarin SK**, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, Chen DS, Chen HL, Chen PJ, Chien RN, Dokmeci AK, Gane E, Hou JL, Jafri W, Jia J, Kim JH, Lai CL, Lee HC, Lim SG, Liu CJ, Locarnini S, Al Mahtab M, Mohamed R, Omata M, Park J, Piratvisuth T, Sharma BC, Sollano J, Wang FS, Wei L, Yuen MF, Zheng SS, Kao JH. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. *Hepatol Int* 2016; **10**: 1-98 [PMID: 26563120 DOI: 10.1007/s12072-015-9675-4]

17 **Liaw YF**, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH, Amarapurkar D, Cooksley G, Jafri W, Mohamed R, Hou JL, Chuang WL, Lesmana LA, Sollano JD, Suh DJ, Omata M. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. *Hepatol Int* 2012; **6**: 531-561 [PMID: 26201469 DOI: 10.1007/s12072-012-9365-4]

18 **Liaw YF**, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S; Chronic Hepatitis B Guideline Working Party of the Asian-Pacific Association for the Study of the Liver. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. *Hepatol Int* 2008; **2**: 263-283 [PMID: 19669255 DOI: 10.1007/s12072-008-9080-3]

19 **Megahed FAK**, Zhou X, Sun P. The Interactions between HBV and the Innate Immunity of Hepatocytes. *Viruses* 2020; **12** [PMID: 32151000 DOI: 10.3390/v12030285]

20 **Han JW**, Shin EC. Liver-Resident Memory CD8+ T Cells: Possible Roles in Chronic HBV Infection. *Int J Mol Sci* 2020; **22** [PMID: 33396596 DOI: 10.3390/ijms22010283]

21 **Faure-Dupuy S**, Lucifora J, Durantel D. Interplay between the Hepatitis B Virus and Innate Immunity: From an Understanding to the Development of Therapeutic Concepts. *Viruses* 2017; **9** [PMID: 28452930 DOI: 10.3390/v9050095]

22 **Bertoletti A**, Ferrari C. Adaptive immunity in HBV infection. *J Hepatol* 2016; **64**: S71-S83 [PMID: 27084039 DOI: 10.1016/j.jhep.2016.01.026]

23 **Zhong B**, Huang MP, Yin GQ, Gao X. Effects of costimulation on intrahepatic immunopathogenesis in patients with chronic HBV infection. *Inflamm Res* 2014; **63**: 217-229 [PMID: 24337678 DOI: 10.1007/s00011-013-0691-3]

24 **Yin JW**, Ping Huang M, Zhong B. Intrahepatic Toll-Like Receptor 3 in Chronic HBV Infection Subjects: Asymptomatic Carriers, Active Chronic Hepatitis, Cirrhosis, and Hepatocellular Carcinoma. *Hepat Mon* 2016; **16**: e34432 [PMID: 27630720 DOI: 10.5812/hepatmon.34432]

25 **Stoop JN**, Claassen MA, Woltman AM, Binda RS, Kuipers EJ, Janssen HL, van der Molen RG, Boonstra A. Intrahepatic regulatory T cells are phenotypically distinct from their peripheral counterparts in chronic HBV patients. *Clin Immunol* 2008; **129**: 419-427 [PMID: 18823821 DOI: 10.1016/j.clim.2008.07.029]

26 **Peppa D**, Micco L, Javaid A, Kennedy PT, Schurich A, Dunn C, Pallant C, Ellis G, Khanna P, Dusheiko G, Gilson RJ, Maini MK. Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. *PLoS Pathog* 2010; **6**: e1001227 [PMID: 21187913 DOI: 10.1371/journal.ppat.1001227]

27 **Pandey S**, Kawai T, Akira S. Microbial sensing by Toll-like receptors and intracellular nucleic acid sensors. *Cold Spring Harb Perspect Biol* 2014; **7**: a016246 [PMID: 25301932 DOI: 10.1101/cshperspect.a016246]

28 **Protzer U**, Maini MK, Knolle PA. Living in the liver: hepatic infections. *Nat Rev Immunol* 2012; **12**: 201-213 [PMID: 22362353 DOI: 10.1038/nri3169]

29 **Wu J**, Meng Z, Jiang M, Pei R, Trippler M, Broering R, Bucchi A, Sowa JP, Dittmer U, Yang D, Roggendorf M, Gerken G, Lu M, Schlaak JF. Hepatitis B virus suppresses toll-like receptor-mediated innate immune responses in murine parenchymal and nonparenchymal liver cells. *Hepatology* 2009; **49**: 1132-1140 [PMID: 19140219 DOI: 10.1002/hep.22751]

30 **Lumley SF**, McNaughton AL, Klenerman P, Lythgoe KA, Matthews PC. Hepatitis B Virus Adaptation to the CD8+ T Cell Response: Consequences for Host and Pathogen. *Front Immunol* 2018; **9**: 1561 [PMID: 30061882 DOI: 10.3389/fimmu.2018.01561]

31 **Boni C**, Barili V, Acerbi G, Rossi M, Vecchi A, Laccabue D, Penna A, Missale G, Ferrari C, Fisicaro P. HBV Immune-Therapy: From Molecular Mechanisms to Clinical Applications. *Int J Mol Sci* 2019; **20** [PMID: 31195619 DOI: 10.3390/ijms20112754]

32 **Hoogeveen RC**, Boonstra A. Checkpoint Inhibitors and Therapeutic Vaccines for the Treatment of Chronic HBV Infection. *Front Immunol* 2020; **11**: 401 [PMID: 32194573 DOI: 10.3389/fimmu.2020.00401]

33 **Murphy CM**, Xu Y, Li F, Nio K, Reszka-Blanco N, Li X, Wu Y, Yu Y, Xiong Y, Su L. Hepatitis B Virus X Protein Promotes Degradation of SMC5/6 to Enhance HBV Replication. *Cell Rep* 2016; **16**: 2846-2854 [PMID: 27626656 DOI: 10.1016/j.celrep.2016.08.026]

34 **Livingston CM**, Ramakrishnan D, Strubin M, Fletcher SP, Beran RK. Identifying and Characterizing Interplay between Hepatitis B Virus X Protein and Smc5/6. *Viruses* 2017; **9** [PMID: 28368357 DOI: 10.3390/v9040069]

35 **Tsunematsu S**, Suda G, Yamasaki K, Kimura M, Izumi T, Umemura M, Ito J, Sato F, Nakai M, Sho T, Morikawa K, Ogawa K, Tanaka Y, Watashi K, Wakita T, Sakamoto N. Hepatitis B virus X protein impairs α-interferon signaling via up-regulation of suppressor of cytokine signaling 3 and protein phosphatase 2A. *J Med Virol* 2017; **89**: 267-275 [PMID: 27459003 DOI: 10.1002/jmv.24643]

36 **Tan G**, Song H, Xu F, Cheng G. When Hepatitis B Virus Meets Interferons. *Front Microbiol* 2018; **9**: 1611 [PMID: 30072974 DOI: 10.3389/fmicb.2018.01611]

37 **Matthews PC**, Carlson JM, Beloukas A, Malik A, Jooste P, Ogwu A, Shapiro R, Riddell L, Chen F, Luzzi G, Jesuthasan G, Jeffery K, Jojic N, Ndung'u T, Carrington M, Goulder PJ, Geretti AM, Klenerman P. HLA-A is a Predictor of Hepatitis B e Antigen Status in HIV-Positive African Adults. *J Infect Dis* 2016; **213**: 1248-1252 [PMID: 26655301 DOI: 10.1093/infdis/jiv592]

38 **Mohamadkhani A**, Sotoudeh M, Bowden S, Poustchi H, Jazii FR, Sayehmiri K, Malekzadeh R. Downregulation of HLA class II molecules by G1896A pre-core mutation in chronic hepatitis B virus infection. *Viral Immunol* 2009; **22**: 295-300 [PMID: 19811086 DOI: 10.1089/vim.2009.0031]

39 **Hakim MS**, Rahmadika N, Jariah ROA. Expressions of inhibitory checkpoint molecules in acute and chronic HBV and HCV infections: Implications for therapeutic monitoring and personalized therapy. *Rev Med Virol* 2020; **30**: e2094 [PMID: 31825155 DOI: 10.1002/rmv.2094]

40 **Beyer M**, Abdullah Z, Chemnitz JM, Maisel D, Sander J, Lehmann C, Thabet Y, Shinde PV, Schmidleithner L, Köhne M, Trebicka J, Schierwagen R, Hofmann A, Popov A, Lang KS, Oxenius A, Buch T, Kurts C, Heikenwalder M, Fätkenheuer G, Lang PA, Hartmann P, Knolle PA, Schultze JL. Tumor-necrosis factor impairs CD4(+) T cell-mediated immunological control in chronic viral infection. *Nat Immunol* 2016; **17**: 593-603 [PMID: 26950238 DOI: 10.1038/ni.3399]

41 **Wilson EB**, Yamada DH, Elsaesser H, Herskovitz J, Deng J, Cheng G, Aronow BJ, Karp CL, Brooks DG. Blockade of chronic type I interferon signaling to control persistent LCMV infection. *Science* 2013; **340**: 202-207 [PMID: 23580528 DOI: 10.1126/science.1235208]

42 **Boni C**, Fisicaro P, Valdatta C, Amadei B, Di Vincenzo P, Giuberti T, Laccabue D, Zerbini A, Cavalli A, Missale G, Bertoletti A, Ferrari C. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. *J Virol* 2007; **81**: 4215-4225 [PMID: 17287266 DOI: 10.1128/JVI.02844-06]

43 **Zhang Z**, Wang C, Liu Z, Zou G, Li J, Lu M. Host Genetic Determinants of Hepatitis B Virus Infection. *Front Genet* 2019; **10**: 696 [PMID: 31475028 DOI: 10.3389/fgene.2019.00696]

44 **O'Brien TR**, Yang HI, Groover S, Jeng WJ. Genetic Factors That Affect Spontaneous Clearance of Hepatitis C or B Virus, Response to Treatment, and Disease Progression. *Gastroenterology* 2019; **156**: 400-417 [PMID: 30287169 DOI: 10.1053/j.gastro.2018.09.052]

45 **Akcay IM**, Katrinli S, Ozdil K, Doganay GD, Doganay L. Host genetic factors affecting hepatitis B infection outcomes: Insights from genome-wide association studies. *World J Gastroenterol* 2018; **24**: 3347-3360 [PMID: 30122875 DOI: 10.3748/wjg.v24.i30.3347]

46 **Wang L**, Zou ZQ, Wang K. Clinical Relevance of HLA Gene Variants in HBV Infection. *J Immunol Res* 2016; **2016**: 9069375 [PMID: 27243039 DOI: 10.1155/2016/9069375]

47 **He D**, Tao S, Guo S, Li M, Wu J, Huang H, Guo X, Yan G, Zhu P, Wang Y. Interaction of TLR-IFN and HLA polymorphisms on susceptibility of chronic HBV infection in Southwest Han Chinese. *Liver Int* 2015; **35**: 1941-1949 [PMID: 25469587 DOI: 10.1111/liv.12756]

48 **Wasityastuti W**, Yano Y, Ratnasari N, Triyono T, Triwikatmani C, Indrarti F, Heriyanto DS, Yamani LN, Liang Y, Utsumi T, Hayashi Y. Protective effects of HLA-DPA1/DPB1 variants against Hepatitis B virus infection in an Indonesian population. *Infect Genet Evol* 2016; **41**: 177-184 [PMID: 27051043 DOI: 10.1016/j.meegid.2016.03.034]

49 **Eskandari E**, Metanat M, Pahlevani E, Nakhzari-Khodakheir T. Association between TGFβ1 polymorphisms and chronic hepatitis B infection in an Iranian population. *Rev Soc Bras Med Trop* 2017; **50**: 301-308 [PMID: 28700046 DOI: 10.1590/0037-8682-0266-2016]

50 **Karra VK**, Gumma PK, Chowdhury SJ, Ruttala R, Polipalli SK, Chakravarti A, Kar P. IL-18 polymorphisms in hepatitis B virus related liver disease. *Cytokine* 2015; **73**: 277-282 [PMID: 25802197 DOI: 10.1016/j.cyto.2015.02.015]

51 **Karataylı SC**, Bozdayı M, Karataylı E, Öztürk T, Husseini AA, Albayrak R, Özkan M, Kalaylıoğlu Z, Yalçın K, Çınar K, İdilman R, Yurdaydın C. Interleukin-28 gene polymorphisms may contribute to HBsAg persistence and the development of HBeAg-negative chronic hepatitis B. *Liver Int* 2015; **35**: 846-853 [PMID: 24840315 DOI: 10.1111/liv.12595]

52 **Talaat RM**, Dondeti MF, El-Shenawy SZ, Khamiss OA. Association between IL-10 gene promoter polymorphism and hepatitis B viral infection in an Egyptian population. *Biochem Genet* 2014; **52**: 387-402 [PMID: 24838671 DOI: 10.1007/s10528-014-9655-8]

53 **Saxena R**, Chawla YK, Verma I, Kaur J. Effect of IL-12B, IL-2, TGF-β1, and IL-4 polymorphism and expression on hepatitis B progression. *J Interferon Cytokine Res* 2014; **34**: 117-128 [PMID: 24161121 DOI: 10.1089/jir.2013.0043]

54 **Nitschke K**, Luxenburger H, Kiraithe MM, Thimme R, Neumann-Haefelin C. CD8+ T-Cell Responses in Hepatitis B and C: The (HLA-) A, B, and C of Hepatitis B and C. *Dig Dis* 2016; **34**: 396-409 [PMID: 27170395 DOI: 10.1159/000444555]

55 **Matsuura K**, Isogawa M, Tanaka Y. Host genetic variants influencing the clinical course of hepatitis B virus infection. *J Med Virol* 2016; **88**: 371-379 [PMID: 26255971 DOI: 10.1002/jmv.24350]

56 **Trinks J**, Nishida N, Hulaniuk ML, Caputo M, Tsuchiura T, Marciano S, Haddad L, Blejer J, Bartoli S, Ameigeiras B, Frías SE, Vistarini C, Heinrich F, Remondegui C, Ceballos S, Echenique G, Charre Samman M, D'Amico C, Rojas A, Martínez A, Ridruejo E, Fernández RJ, Burgos Pratx L, Salamone H, Nuñez F, Galdame O, Gadano A, Corach D, Sugiyama M, Flichman D, Tokunaga K, Mizokami M. Role of HLA-DP and HLA-DQ on the clearance of hepatitis B virus and the risk of chronic infection in a multiethnic population. *Liver Int* 2017; **37**: 1476-1487 [PMID: 28267888 DOI: 10.1111/liv.13405]

57 **Tan AT**, Loggi E, Boni C, Chia A, Gehring AJ, Sastry KS, Goh V, Fisicaro P, Andreone P, Brander C, Lim SG, Ferrari C, Bihl F, Bertoletti A. Host ethnicity and virus genotype shape the hepatitis B virus-specific T-cell repertoire. *J Virol* 2008; **82**: 10986-10997 [PMID: 18799575 DOI: 10.1128/JVI.01124-08]

58 **McLane LM**, Abdel-Hakeem MS, Wherry EJ. CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. *Annu Rev Immunol* 2019; **37**: 457-495 [PMID: 30676822 DOI: 10.1146/annurev-immunol-041015-055318]

59 **Thomas R**, Thio CL, Apps R, Qi Y, Gao X, Marti D, Stein JL, Soderberg KA, Moody MA, Goedert JJ, Kirk GD, Hoots WK, Wolinsky S, Carrington M. A novel variant marking HLA-DP expression levels predicts recovery from hepatitis B virus infection. *J Virol* 2012; **86**: 6979-6985 [PMID: 22496224 DOI: 10.1128/JVI.00406-12]

60 **Al-Qahtani AA**, Al-Anazi MR, Abdo AA, Sanai FM, Al-Hamoudi W, Alswat KA, Al-Ashgar HI, Khalaf NZ, Eldali AM, Viswan NA, Al-Ahdal MN. Association between HLA variations and chronic hepatitis B virus infection in Saudi Arabian patients. *PLoS One* 2014; **9**: e80445 [PMID: 24465366 DOI: 10.1371/journal.pone.0080445]

61 **Lok AS**, Zoulim F, Dusheiko G, Ghany MG. Hepatitis B cure: From discovery to regulatory approval. *J Hepatol* 2017; **67**: 847-861 [PMID: 28778687 DOI: 10.1016/j.jhep.2017.05.008]

62 **Boyd A**, Lacombe K, Lavocat F, Maylin S, Miailhes P, Lascoux-Combe C, Delaugerre C, Girard PM, Zoulim F. Decay of ccc-DNA marks persistence of intrahepatic viral DNA synthesis under tenofovir in HIV-HBV co-infected patients. *J Hepatol* 2016; **65**: 683-691 [PMID: 27210429 DOI: 10.1016/j.jhep.2016.05.014]

63 **Martinez MG**, Testoni B, Zoulim F. Biological basis for functional cure of chronic hepatitis B. *J Viral Hepat* 2019; **26**: 786-794 [PMID: 30803126 DOI: 10.1111/jvh.13090]

64 **Yin GQ**, Li J, Zhong B, Yang YF, Wang MR. New therapeutic options for persistent low-level viremia in patients with chronic hepatitis B virus infection: Increase of entecavir dosage. *World J Gastroenterol* 2021; **27**: 666-676 [PMID: 33716446 DOI: 10.3748/wjg.v27.i8.666]

65 **Goh ZY**, Ren EC, Ko HL. Intracellular interferon signalling pathways as potential regulators of covalently closed circular DNA in the treatment of chronic hepatitis B. *World J Gastroenterol* 2021; **27**: 1369-1391 [PMID: 33911462 DOI: 10.3748/wjg.v27.i14.1369]

66 **Liang TJ**, Block TM, McMahon BJ, Ghany MG, Urban S, Guo JT, Locarnini S, Zoulim F, Chang KM, Lok AS. Present and future therapies of hepatitis B: From discovery to cure. *Hepatology* 2015; **62**: 1893-1908 [PMID: 26239691 DOI: 10.1002/hep.28025]

67 **Meng Z**, Chen Y, Lu M. Advances in Targeting the Innate and Adaptive Immune Systems to Cure Chronic Hepatitis B Virus Infection. *Front Immunol* 2019; **10**: 3127 [PMID: 32117201 DOI: 10.3389/fimmu.2019.03127]

68 **Lee S**, Baldridge MT. Interferon-Lambda: A Potent Regulator of Intestinal Viral Infections. *Front Immunol* 2017; **8**: 749 [PMID: 28713375 DOI: 10.3389/fimmu.2017.00749]

69 **Liu SY**, Aliyari R, Chikere K, Li G, Marsden MD, Smith JK, Pernet O, Guo H, Nusbaum R, Zack JA, Freiberg AN, Su L, Lee B, Cheng G. Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol. *Immunity* 2013; **38**: 92-105 [PMID: 23273844 DOI: 10.1016/j.immuni.2012.11.005]

70 **Ji M**, Hu K. Recent advances in the study of hepatitis B virus covalently closed circular DNA. *Virol Sin* 2017; **32**: 454-464 [PMID: 29280054 DOI: 10.1007/s12250-017-4009-4]

71 **Kim W**, Lee S, Son Y, Ko C, Ryu WS. DDB1 Stimulates Viral Transcription of Hepatitis B Virus via HBx-Independent Mechanisms. *J Virol* 2016; **90**: 9644-9653 [PMID: 27535046 DOI: 10.1128/JVI.00977-16]

72 **Tropberger P**, Mercier A, Robinson M, Zhong W, Ganem DE, Holdorf M. Mapping of histone modifications in episomal HBV cccDNA uncovers an unusual chromatin organization amenable to epigenetic manipulation. *Proc Natl Acad Sci U S A* 2015; **112**: E5715-E5724 [PMID: 26438841 DOI: 10.1073/pnas.1518090112]

73 **Dandri M**. Epigenetic modulation in chronic hepatitis B virus infection. *Semin Immunopathol* 2020; **42**: 173-185 [PMID: 32185454 DOI: 10.1007/s00281-020-00780-6]

74 **Brouwer WP**, Chan HLY, Lampertico P, Hou J, Tangkijvanich P, Reesink HW, Zhang W, Mangia A, Tanwandee T, Montalto G, Simon K, Ormeci N, Chen L, Tabak F, Gunsar F, Flisiak R, Ferenci P, Akdogan M, Akyuz F, Hirankarn N, Jansen L, Wong VW, Soffredini R, Liang X, Chen S, Groothuismink ZMA, Santoro R, Jaroszewicz J, Ozaras R, Kozbial K, Brahmania M, Xie Q, Chotiyaputta W, Xun Q, Pazgan-Simon M, Oztas E, Verhey E, Montanari NR, Sun J, Hansen BE, Boonstra A, Janssen HLA; GIANT-B Global Consortium. Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study. *Clin Infect Dis* 2019; **69**: 1969-1979 [PMID: 30715261 DOI: 10.1093/cid/ciz084]

75 **Thanapirom K**, Suksawatamnuay S, Sukeepaisarnjareon W, Tanwandee T, Charatcharoenwitthaya P, Thongsawat S, Leerapun A, Piratvisuth T, Boonsirichan R, Bunchorntavakul C, Pattanasirigool C, Pornthisarn B, Tantipanichtheerakul S, Sripariwuth E, Jeamsripong W, Sanpajit T, Poovorawan Y, Komolmit P. Genetic variation in the vitamin D pathway CYP2R1 gene predicts sustained HBeAg seroconversion in chronic hepatitis B patients treated with pegylated interferon: A multicenter study. *PLoS One* 2017; **12**: e0173263 [PMID: 28296915 DOI: 10.1371/journal.pone.0173263]

76 **Jiang DK**, Wu X, Qian J, Ma XP, Yang J, Li Z, Wang R, Sun L, Liu F, Zhang P, Zhu X, Wu J, Chen K, Conran C, Zheng SL, Lu D, Yu L, Liu Y, Xu J. Genetic variation in STAT4 predicts response to interferon-α therapy for hepatitis B e antigen-positive chronic hepatitis B. *Hepatology* 2016; **63**: 1102-1111 [PMID: 26704347 DOI: 10.1002/hep.28423]

77 **Tseng TC**, Yu ML, Liu CJ, Lin CL, Huang YW, Hsu CS, Liu CH, Kuo SF, Pan CJ, Yang SS, Su CW, Chen PJ, Chen DS, Kao JH. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy. *Antivir Ther* 2011; **16**: 629-637 [PMID: 21817184 DOI: 10.3851/IMP1841]

78 **Wu X**, Shi W, Wu J, Zhu X, Chen K, Zheng S, Li Z, Duan Z, Li H, Liu Y. A functional polymorphism in ADAR1 gene affects HBsAg seroclearance both spontaneously and interferon induced. *Liver Int* 2014; **34**: 1560-1565 [PMID: 24351124 DOI: 10.1111/liv.12444]

79 **Konerman MA**, Lok AS. Interferon Treatment for Hepatitis B. *Clin Liver Dis* 2016; **20**: 645-665 [PMID: 27742005 DOI: 10.1016/j.cld.2016.06.002]

80 **Sokal EM**, Conjeevaram HS, Roberts EA, Alvarez F, Bern EM, Goyens P, Rosenthal P, Lachaux A, Shelton M, Sarles J, Hoofnagle J. Interferon alfa therapy for chronic hepatitis B in children: a multinational randomized controlled trial. *Gastroenterology* 1998; **114**: 988-995 [PMID: 9558288 DOI: 10.1016/s0016-5085(98)70318-x]

81 **Roberts EA**. Why treat chronic hepatitis B in childhood with interferon alpha? *Gut* 2000; **46**: 591-593 [PMID: 10764697 DOI: 10.1136/gut.46.5.591a]

82 **Chu CM**, Liaw YF. Hepatitis B surface antigen seroclearance during chronic HBV infection. *Antivir Ther* 2010; **15**: 133-143 [PMID: 20386068 DOI: 10.3851/IMP1497]

83 **Wu H**, Zhao G, Qian F, Liu K, Xie J, Zhou H, Xu J, Xu Y, Han Y, Xie Q, Wang H. Association of IL28B polymorphisms with peginterferon treatment response in Chinese Han patients with HBeAg-positive chronic hepatitis B. *Liver Int* 2015; **35**: 473-481 [PMID: 24517415 DOI: 10.1111/liv.12491]

84 **Chang ML**, Liaw YF. Hepatitis B Flare in Hepatitis B e Antigen-Negative Patients: A Complicated Cascade of Innate and Adaptive Immune Responses. *Int J Mol Sci* 2022; **23** [PMID: 35163476 DOI: 10.3390/ijms23031552]

85 **Cao Z**, Liu Y, Ma L, Lu J, Jin Y, Ren S, He Z, Shen C, Chen X. A potent hepatitis B surface antigen response in subjects with inactive hepatitis B surface antigen carrier treated with pegylated-interferon alpha. *Hepatology* 2017; **66**: 1058-1066 [PMID: 28407271 DOI: 10.1002/hep.29213]

86 **Wu F**, Lu R, Liu Y, Wang Y, Tian Y, Li Y, Li M, Wang W, Zhang X, Jia X, Dang S. Efficacy and safety of peginterferon alpha monotherapy in Chinese inactive chronic hepatitis B virus carriers. *Liver Int* 2021; **41**: 2032-2045 [PMID: 33896094 DOI: 10.1111/liv.14897]

87 **Huang Y**, Qi M, Liao C, Xun J, Zou J, Huang H, Long LY, Chen J, Fan X, Chen R. Analysis of the Efficacy and Safety of PEGylated Interferon-α2b Treatment in Inactive Hepatitis B Surface Antigen Carriers. *Infect Dis Ther* 2021; **10**: 2323-2331 [PMID: 34350562 DOI: 10.1007/s40121-021-00511-w]

88 **Li MH**, Xie Y, Zhang L, Lu Y, Shen G, Wu SL, Chang M, Mu CQ, Hu LP, Hua WH, Song SJ, Zhang SF, Cheng J, Xu DZ. Hepatitis B surface antigen clearance in inactive hepatitis B surface antigen carriers treated with peginterferon alfa-2a. *World J Hepatol* 2016; **8**: 637-643 [PMID: 27239256 DOI: 10.4254/wjh.v8.i15.637]

89 **Terrault NA**, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, Brown RS Jr, Bzowej NH, Wong JB. Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. *Clin Liver Dis (Hoboken)* 2018; **12**: 33-34 [PMID: 30988907 DOI: 10.1002/cld.728]

90 **European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu.**; European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. *J Hepatol* 2017; **67**: 370-398 [PMID: 28427875 DOI: 10.1016/j.jhep.2017.03.021]

91 **Cusato J**, Boglione L, De Nicolò A, Imbornone R, Cardellino CS, Ghisetti V, Carcieri C, Cariti G, Di Perri G, D'Avolio A. Association of vitamin D pathway SNPs and clinical response to interferon in a cohort of HBeAg-negative patients. *Pharmacogenomics* 2017; **18**: 651-661 [PMID: 28453395 DOI: 10.2217/pgs-2016-0041]

**Footnotes**

**Conflict-of-interest statement:** All theauthors report no relevant conflicts of interest for this article.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Unsolicited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Peer-review started:** May 10, 2022

**First decision:** August 20, 2022

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** China

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C, C

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Jha P, United States; Leowattana W, Thailand **S-Editor:** Fan JR **L-Editor:** A **P-Editor:** Fan JR

**Figure Legends**



**Figure 1 Crosstalk among immune cells and cytokines in hepatitis B virus infection.** The complex interactions among immune cells and cytokines in chronic hepatitis B are shown. Hepatitis B virus (HBV)-specific CD8+ T-cells are activated by monocytes and CD4+ T-cells, followed by recruitment and activation of macrophages by active CD8+ T-cells. The activation of natural killer (NK) T-cells is induced by Kupffer cells, which activate NK cells and hepatic stellate cells (HSCs). Suppressive Tregs, Bregs and Kupffer cells induce the functional impairment of CD8+ T cells, CD4+ T-cells and NK cells. Moreover, Treg cells, Kupffer cells and myeloid-derived suppressor cells can lead to the exhaustion of CD8+ T-cells and NK cells. Inflammatory and inhibitory cytokines, including Monocyte chemoattractant protein-1, tumor necrosis factor-α, interferon-γ, interleukin (IL)-4, IL-6, IL-12, IL-13, IL-17, IL-10, and transforming growth factor-β, are involved in the crosstalk among immune cells. The activation of HSCs in sinusoids is induced by a complement protein such as C5a. Finally, decreasing epigenetic modification and function of HBV-specific CD8+ T-cells inhibits the immune control of HBV. PD-1: Programmed death 1; CTLA-4: Cytotoxic T-lymphocyte antigen-4; IL: Interleukin; TNF-α: Tumor necrosis factor-α; TGF-β: Transforming growth factor β; IFN-γ: Interferon-γ; HSC: Hepatic stellate cell; MDSC: Myeloid-derived suppressor cells; NK: Natural killer.



**Figure 2 Mechanism of immune escape in antigen-presenting cell/hepatitis B virus special T-cell.** Hepatitis B virus (HBV)-infected hepatocytes produce various HBV antigens that are swallowed and digested by antigen-presenting cells (APCs), producing HBV peptide/human leukocyte antigen (HLA) complexes. Antigen processing escape mutants, down-regulating HLA expression and mutation of HLA binding residues may appear in APCs. The HBV peptide/HLA complexes are transferred to the surface of APC and make contact with T-cell receptor (TCR) on the surface of CD8+ T-cells. Masking HLA/TCT binding residues with N-linked glycosylation and mutation of TCR binding residues influences TCR afﬁnity/avidity, leading to CD8+ T-cell stimulation or inhibition. The square icon displays: (1) Increase in viral antigen; (2) Antigen processing escape mutants; (3) Down-regulation of HLA expression; (4) Mutation of HLA binding residues; (5) Masking of HLA/TCT binging residues with N-linked glycosylation; (6) Mutation of TCR binding residues; (7) Stimulation induced by cytokine production and cytolytic activity; and (8) Inhibition caused by exhaustion, anergy and tolerance. HBV: Hepatitis B virus; TCR: T-cell receptor; HLA: Human leukocyte antigen.

****

**Figure 3 Interplay between hepatitis B virus-specific immune control, hepatitis B virus components, and negative feedback regulation in immunity and host genes.** HBV: Hepatitis B virus.



**Figure 4 Interferon-α retreatment improves the efficacy of hepatitis B virus-specific immune control.** Interferon-α (IFN-α) retreatment can lead to various treatment outcomes, namely no response, hepatitis B virus (HBV) decline, partial cure and functional cure. Multiple frequencies of IFN-α treatment can potentially restore specific immune control to HBV infection and simultaneously increase the rate of partial cure and functional cure. A: Exhausted immune control to HBV before IFN-α therapy (Baseline); B: Without HBV decline following IFN-α therapy; C: HBV decline; D: Partial cure; E: Functional cure. CHB: Chronic hepatitis B.

**Table 1 Immune cells and their corresponding cytokines released**

|  |  |
| --- | --- |
| **Immune cells** | **Released cytokines** |
| NK cells  | IFN-γ, TNF-α, IL-10 |
| NKT cells  | IFN-γ, IL-4, IL-13 |
| Monocytes | IFN-γ, TNF-α, IL-10 |
| Macrophages | IFN-γ, IL-6, MCP-1, IL-1β, TNF-α, CXCL10 |
| γδT cells | IL-17, TNF-α |
| HSCs | IL-1β, IL-6, TGF-β |
| Kupffer cells | IL-10, TGF-β, IL-12, IL-6, TNF-α |
| CD8+ T cells | IFN-γ, TNF-α, IL-2, IL-10, IL-17, IL-21 |
| CD4+ T cells  | IFN-γ, IL-21,IL-17 |
| Regulatory T cells | IL-10, TGF-β, IL-35 |
| Regulatory B cells  | IL-10 |

HSCs: Hepatic stellate cells; IL: Interleukin; TGF-β: Transforming growth factor β; TNF-α: Tumor necrosis factor-α; IFN-γ: Interferon-γ; NK: Natural killer.

**Table 2 Host genetic variants associated with hepatitis B virus infection**[43-46]

|  |  |  |
| --- | --- | --- |
| **Gene ontology**  | **Gene**  | **Genetic determinants (SNP/Hap/CNVs)**  |
| HLA | *HLA-A*  | \*33:03:01  |
|  | *HLA-B*  | \*13:01:01  |
|  | *HLA-B*  | \*07, \*58  |
|  | *HLA-C*  | Leu-15, rs2853953, rs3130542  |
|  | *HLA-DOA*  | rs378352  |
|  | *HLA-DP*  | rs9366816  |
|  | *HLA-DPA1*  | rs3077, rs2301220, rs2395309, rs9277341 |
|  | *HLA-DPB1*  | G-A-G-A-T-T1, G-G-G-G-T-C2, rs2281388, rs9277535, rs9277542, rs9277534, \*0201, \*0401, \*0901, positions 84–87, \*0402, \*0501, \*0201-\*0401, \*0201-\*0402, \*0201-\*0501, \*0401-\*0402, \*0401-\*0501, \*0402-\*0402, \*0402-\*0501, \*0501-\*0501, \*0501- \*0901, \*0501\*others, rs9277378, rs10484569, rs3117222, rs9380343, rs3135021 |
|  | *HLA-DQ*  | rs9275319, rs9275572, A1\*0101-B1\*0501, A1\*0102-B1\*0303, A1\*0102-B1\*0604, A1\*0301-B1\*0601, A1\*0102-B1\*0602, A1\*0102-B1\*0602, A1\*0301-B1\*0302, A1\*0301-B1\*0303, A1\*0301-B1\*0401, A1\*0501-B1\*0301 |
|  | *HLA-DPA1/ DPB1*  | A-A3, A-A4, T-A-T5,C-A-T6, A-A-C-T7, A-A-C-C//A-G-T-G-C-C8, A-A-C-T//A-G-T-G-C-C9, G-G-T-C//A-G-T-G-C-C10, A1\*0103-B1\*0401, A1\*0103-B1\*0402, A1\*0202-B1\*0301, A1\*0202-B1\*0501 |
|  | *HLA-DQA2*  | rs9276370 |
|  | *HLA-DQB1*  | \*0201, \*0301, \*0303, \*0502, \*0604, rs2856718, \*0401-\*0501, \*0402-\*0402, \*0402-\*0501, \*0501-\*0501 |
|  | *HLA-DQB2*  | rs7453920, rs7756516 |
|  | *HLA-DRB1*  | \*13 |
|  | *HLA-DP/DQ*  | T-T-G-A-T11, T-T-G-G-T12, carrying 4–6 variant alleles, G-A13, A-G14, A-A15 |
|  | *HLA-J* | rs400488 |
| Cytokines  | *IL-10*  | −592  |
|  | *IL-10RB*  | rs2834167  |
|  | *IL-12B*  | rs3212227  |
|  | *IL-16*  | rs11556218  |
|  | *IL-21*  | rs2221903  |
|  | *IL-12B*  | rs3212227  |
|  | *IL-18*  | −137  |
|  | *IFN-γ*  | +874  |
|  | *IFN-α2*  | p.Ala120Thr  |
|  | *IFN-αR2*  | rs1051393, rs12233338  |
|  | *IFNLR1*  | rs4649203, rs7525481  |
|  | *IFN-γR1*  | rs3799488  |
|  | *IFN-γR2*  | rs1059293  |
|  | *TNF-α*  | T-C-C-G-G-G16, C-A-C-G-G-G17 ,−238, −308, −857, −863 |
|  | *TGF-α*  | +106151, +103461, A-T-G-T-T-T-T-C-T18 |
| Chemokines | *CCR5*  | Δ32  |
| TLRs  | *TLR-3*  | rs3775291, rs1879026 |
|  | *TLR-9*  | rs352140  |
| MicroRNAs | *miR-30a*  | rs1358379  |
|  | *miR-101-2*  | T-C19, rs12375841 |
|  | *miR-106b-25*  | rs999885  |
|  | *miR-122*  | rs3783553, rs4309483  |
|  | *miR-196a-2*  | rs11614913  |
|  | *miR-let-7c*  | rs6147150  |
|  | *miR-219-1*  | rs107822, rs213210, rs421446, C-A-C20, T-G-T21 |
|  | *miR-323b*  | rs56103835  |
|  | *miR-423*  | rs6505162  |
|  | *miR-492*  | rs2289030  |
| Others | *C2*  | p.Glu318Asp, rs7746553, rs9267673, rs9267665, rs9267677, rs9279450, rs10947223  |
|  | *CD40*  | rs1883832  |
|  | *CFB*  | rs12614  |
|  | *CTLA-4*  | C-A-C-C-G22, T/C-A-C-C-G23, T-A-C-C-A24, rs231775,rs3087243, rs5742909 |
|  | *EHMT2*  | rs7887, rs652888, rs35875104, rs41267090  |
|  | *ESR1*  | +29  |
|  | *IFN4/HLA-DQ*  | rs12971396-rs9275319, rs12971396-rs12979860-rs9275319  |
|  | *INST10*  | rs7000921  |
|  | *KIF1B*  | A-T-A25 |
|  | *MCP1*  | −2518, −2518/−2076(−/ht2), −2518/−2076(ht2/ht2)  |
|  | *MIF*  | rs755622  |
|  | *MxA* | −123  |
|  | *MX1*  | rs467960  |
|  | *NF-κB* | rs2233406, rs3138053  |
|  | *NLRX1*  | p.Arg707Cys  |
|  | *NOTCH4*  | rs422951  |
|  | *NTCP*  | rs2296651, rs943277, rs4646285  |
|  | *OCT4*  | rs13409, rs885952, rs879882, rs1265163, rs2394882, rs3094193, rs3130501, rs3130503, rs3130931, rs3132526, rs3757349, rs9263800, rs117265349  |
|  | *PAPL*  | rs423058  |
|  | *SOCS3*  | C-C26, T-T-C-T-A27, rs111033850, rs12953258,  |
|  | *SPP1*  | −1800  |
|  | *STAT4*  | C-T-C-T-T28, rs7574865,rs8179673, rs10168266, rs11889341, |
|  | *TCF19*  | rs1419881  |
|  | *TMEM2*  | p.Ser1254Asn  |
|  | *TMEM2/IFNA2/ NLRX1/C2*  | p.Ser1254-Asn/p.Ala120Thr/p.Arg707Cys/p.Glu318Asp  |
|  | *UBE2L3*  | rs2266959, rs4821116  |
|  | *VARS2*  | rs1043483, rs1264295, rs2249464, rs2517459, rs2532932, rs9394021,  |
|  | *VDR*  | FokI |
|  | *ZNRD1*  | G-G-A29, rs3757328 |

Haplotypes.

1G-A-G-A-T-T, rs9277535-rs10484569-rs3128917-rs2281388-rs3117222-rs9380343.

2G-G-G-G-T-C, rs9277535-rs10484569-rs3128917-rs2281388-rs3117222-rs9380343.

3A-A, rs3077-rs9277535.

4A-A, rs2395309-rs9277535.

5T-A-T, rs3077-rs9277378-rs3128917.

6C-A-T, rs3077-rs9277378-rs3128917.

7A-A-C-T, rs2395309-rs3077- rs2301220-rs9277341.

8A-A-C-C//A-G-T-G-C-C, rs2395309-rs3077-rs2301220-rs9277341//rs9277535-rs10484569-rs3128917 -rs2281388-rs3117222-rs9380343.

9A-A-C-T//A-G-T-G-C-C, rs2395309-rs3077-rs2301220-rs9277341//rs9277535-rs10484569-rs3128917 -rs2281388-rs3117222-rs9380343.

10G-G-T-C//A-G-T-G-C-C, rs2395309-rs3077-rs2301220-rs9277341//rs9277535-rs10484569-rs3128917 -rs2281388-rs3117222-rs9380343;

11T-T-G-A-T, rs9276370-rs7756516-rs7453920- rs9277535-rs9366816.

12T-T-G-G-T, rs9276370-rs7756516-rs7453920-rs9277535-rs9366816.

13G-A, rs2856718- rs9275572.

14A-G, rs2856718- rs9275572.

15A-A, rs2856718- rs9275572.

16T-C-C-G-G-G, -1031/-863/-857/-308/-238/-163.

17C-A-C-G-G-G, -1031/-863/-857/-308/-238/-163.

18A-T-G-T-T-T-T-C-T, +88344/+102906/+103432/+103437/+103461/+104261/+104802/+106151/+106318.

19T-C, rs12375841-rs17803780.

20C-A-C, rs421446-rs107822-rs213210.

21T-G-T, rs421446-rs107822-rs213210.

22C-A-C-C-G, -1722/-1661/-658/-319/+49.

23T/C-A-C-C-G, -1722/-1661/-658/-319/+49.

24T-A-C-C-A, -1722/-1661/-658/-319/+49.

25A-T-A, rs17401966-rs12734551-rs3748578.

26C-C, rs111033850-rs12953258.

27T-T-C-T-A, -1800/-1627/+4645/+5806/+6139.

28C-T-C-T-T, rs8179673-rs7574865-rs4274624-rs11889341-rs10168266.

29G-G-A, rs3757328-rs6940552-rs9261204.

SNPs/Hap/CNVs: Single nucleotide polymorphisms/Haplotype/Copy number variations; HLA: Human leukocyte antigen; TLR: Toll-like receptors.

**Table 3 Host genetic variants associated with interferon-α therapy**[43,44,74-78,91]

|  |  |  |
| --- | --- | --- |
| **Gene ontology**  | **Gene**  | **Genetic determinants (SNP/Hap/CNVs)**  |
| HLA  | *HLA-DP*  | rs3077, rs9277535  |
|  | *HLA-DQA1-DQB1-DRB1*  | \*0302-\*0303-\*09  |
|  | *HLA-DQB1*  | \*0303  |
|  | *HLA-DRB1*  | \*08  |
|  | *HLA-A, B, C*  | \*1101-\*4601-\*0102  |
| Cytokines  | *IL-28B*  | A-C1,rs8099917, rs12979860, rs12980275 |
| Others  | *CYP24A1*  | rs2248359  |
|  | *CYP27B1*  | rs10877012, rs4646536  |
|  | *G3BP2*  | rs3821977  |
|  | *OAS*  | G-T-G-A2, C-C-T-A3, C-C-C-A4, A-C-T-A5 |
|  | *OAS3*  | rs2072136  |
|  | *PRELID2*  | rs371991  |
|  | *STAT4*  | rs7574865  |
|  | *TRAPPC9*  | rs78900671  |
|  | *VDBP*  | rs7041  |
|  | *VDR*  | rs1544410, rs731236, rs11568820, rs10735810  |

Haplotypes.

1A-C, rs12980275-rs12979860.

2G-T-G-A, rs3177979-rs1293747-rs4767043-rs10849829.

3C-C-T-A, rs2285934-rs2072138-rs2072136-rs10849829.

4C-C-C-A, rs2285934- rs2072138-rs2072136-rs10849829.

5A-C-T-A, rs2285934-rs2072138-rs2072136-rs10849829.

SNPs/Hap/CNVs: Single nucleotide polymorphisms/Haplotype/Copy number variations; HLA: Human leukocyte antigen.

**Table 4 Summary and timeline of interferon-α retreatment for chronic hepatitis B virus infection**

|  |  |  |
| --- | --- | --- |
| **Ref.** | **Year** | **The regimens of INF-α retreatment** |
| van Zonneveld *et al*[10] | 2004 | One hundred and sixty-five patients received their first IFN-α treatment. Of them, 48 non-responders received 2-3 courses of IFN-α |
| Manesis and Hadziyannis[11] | 2001 | Two hundred and sixteen patients received IFN-α therapy, of whom 51 received a second IFN-α treatment and 9 were treated with three courses of IFN-α |
| Niederau *et al*[12] | 1996 | One hundred and three cases were treated IFN-α. Of them, 29 received a second course of therapy, and 17 received a third course of IFN-α |
| Carreño *et al*[13] | 1999 | Fifty-seven patients underwent a course of IFN-α therapy. Of them, 27 received a second course of IFN-α; and 30 others who did not receive IFN-α retreatment served as controls. IFN-α retreatment was found to enhance the antiviral effects against HBV |
| Ballauff *et al*[14] | 1998 | After all the children received the first course of IFN-α treatment, 15 were given the second course of IFN-α (study group), while the other 19 did not receive the second course of IFN-α, serving as the control group. HBV DNA clearance and anti-HBe seroconversion occurred in 5 of 15 children (33%) in the study group and 5 of 19 children (26%) in the control group |
| Yin and Zhong[15] | 2016 | Inappropriate therapies induced HBV resistance, multi-drug resistance and failure of combination therapy with nucleoside plus nucleotide in China. An IFN-α regimen, *i.e.* (1) Switch from nucleoside plus nucleotide to IFN-α therapy; and (2) subsequent IFN-α retreatment, was used to treat these patients. IFN-α switching therapy leaded to safe cessation of nucleoside plus nucleotide combination therapy, and IFN-α retreatment induced sustained response of IFN-α |
| Sarin *et al*[16] | 2016 | Asian-Pacific clinical practice guidelines 2015 recommended IFN-α retreatment to treat chronic HBV infection |
| Liaw *et al*[17] | 2012 | Asian-Pacific clinical practice guidelines 2012 recommended IFN-α retreatment to treat chronic HBV infection |
| Liaw *et al*[18] | 2008 | Asian-Pacific clinical practice guidelines 2008 recommended IFN-α retreatment to treat chronic HBV infection |
| Yin *et al*[64] | 2021 | IFN-α retreatment was recommended for patients on entecavir or tenofovir monotherapy with persistent low-level viremia |

IFN-α: Interferon-α; HBV: Hepatitis B virus.